Ensysce Biosciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ENSC Nasdaq 2830 www.ensysce.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ensysce Biosciences, Inc.

Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation - Sep 2nd, 2026 6:30 am
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study - Aug 31st, 2026 6:30 am
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium - Aug 20th, 2026 6:00 am
ENSC Sets Itself Up Nicely for Critical Stage - Aug 14th, 2026 6:12 am
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Aug 13th, 2026 2:15 pm
Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing - Aug 6th, 2026 8:50 am
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing - Aug 6th, 2026 6:00 am
ENSC Makes Bold Move that Bolsters Pipeline and Finances - Aug 6th, 2026 5:25 am
Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development - Jul 14th, 2026 8:45 am
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant - Jul 14th, 2026 6:00 am
ENSC Receives Vital Funding for Drive to Commercialization - Jul 14th, 2026 5:58 am
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth - Jul 13th, 2026 2:05 pm
Postoperative Pain - Pipeline Insight, 2026 Now Available; Comprehensive Profiles of 40+ Key Players Including Ensysce Biosciences and Allay Therapeutics - Jul 9th, 2026 8:41 am
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study - Jun 26th, 2026 6:00 am
ENSC Advancing Testing and Expanding Potential - May 18th, 2026 5:04 am
Ensysce Biosciences Reports First Quarter 2026 Financial Results - May 15th, 2026 2:15 pm
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology - May 12th, 2026 6:00 am
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam - May 8th, 2026 6:00 am
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study - Apr 16th, 2026 6:00 am
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs - Apr 7th, 2026 6:00 am